Table 1.
Clinical and rheumatologic characteristics, lung function, and microbiology data.
| Total | No pain | Pain | p-value | |
|---|---|---|---|---|
| n | 47 | 25 (53) | 22 (47) | |
| Male | 34 (72) | 20 (80) | 14 (64) | 0.211 |
| Age, years | 28 ± 9 | 30 ± 10 | 26 ± 8 | 0.121 |
| Height, cm | 170 ± 8 | 172 ± 9 | 167 ± 7 | 0.023 |
| Weight, kg | 63 ± 12 | 65 ± 14 | 60 ± 11 | 0.228 |
| BMI, kg/m2 | 22 ± 3 | 22 ± 3 | 22 ± 3 | 0.773 |
| CFTR mutation | ||||
| ΔF508 homozygous | 19 (40) | 6 (24) | 13 (59) | 0.014 |
| ΔF508 heterozygous | 24 (51) | 16 (64) | 8 (36) | 0.059 |
| Other | 4 (8) | 3 (12) | 1 (4) | 0.611 |
| Pancreatic insufficiency | 37 (79) | 18 (72) | 19 (86) | 0.230 |
| Diabetes | 16 (34) | 7 (28) | 9 (41) | 0.351 |
| Depression | 7 (15) | 4 (16) | 3 (14) | 0.820 |
| Osteoporosis | 9 (22) | 4 (20) | 5 (28) | 0.573 |
| Rheumatologic symptoms | ||||
| Spinal pain | 15 (32) | 0 | 15 (68) | – |
| Joint's pain | 14 (30) | 0 | 14 (64) | – |
| Swelling joints | 1 (2) | 1 (4) | 0 | 0.343 |
| Morning joint stiffness > 30 min | 4 (8) | 1 (4) | 3 (14) | 0.237 |
| Exacerbation in the last year | 31 (66) | 16 (64) | 15 (68) | 0.682 |
| Number of episodes per patient | 2.3 ± 1.4 | 2.5 ± 1.5 | 2.2 ± 1.3 | 0.561 |
| Chronic bacterial colonization | ||||
| Pseudomonas aeruginosa | 19 (40) | 12 (48) | 7 (32) | 0.241 |
| Staphylococcus aureus | 34 (72) | 14 (56) | 20 (91) | 0.008 |
| Spirometry | ||||
| FEV1, % | 63 ± 30 | 58 ± 28 | 68 ± 32 | 0.245 |
| TLC, % | 111 ± 13 | 109 ± 13 | 115 ± 12 | 0.255 |
| 6-min walking test | ||||
| Distance, % | 80 ± 11 | 84 ± 10 | 74 ± 10 | 0.050 |
Data are expressed as frequency (percentage) or mean ± standard deviation.
BMI, body mass index; CFTR, cystic fibrosis transmembrane conductance regulator; FEV1, forced expiratory volume at first second; TLC, total lung capacity.